Founded in 2008, we are a biotechnology company focused on the in-house discovery and development of innovative therapies for chronic diseases with a particular emphasis on metabolic disorders. We aspire to bring innovative and effective treatment options to global patients with chronic diseases.

We focus on leveraging accumulated industry experience and established R&D capabilities for the discovery and development of differentiated therapeutics. We have cultivated a diverse pipeline of six product candidates to capture the significant market potential in prevalent chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC) and congenital hyperinsulinemia.